Overview

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Status:
Active, not recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to look at the effectiveness, safety, and antitumor activity (preventing growth of the tumor) of the experimental study drug rucaparib (also known as CO-338) on subjects and on their pancreatic cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Treatments:

Rucaparib